S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
Log in

NYSE:ARA - American Renal Associates Stock Price, Forecast & News

$7.01
-0.35 (-4.76 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$6.97
Now: $7.01
$7.41
50-Day Range
$6.51
MA: $8.30
$9.27
52-Week Range
$5.48
Now: $7.01
$13.80
Volume107,842 shs
Average Volume96,094 shs
Market Capitalization$231.31 million
P/E Ratio26.96
Dividend YieldN/A
Beta2.01
American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of June 30, 2018, it owned and operated 233 dialysis clinics in partnership with 400 nephrologist partners treating approximately 16,000 patients in 26 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.
Read More
American Renal Associates logo

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone978-922-3080

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$822.52 million
Cash Flow$1.61 per share
Book Value$2.59 per share

Profitability

Net Income$-13,790,000.00

Miscellaneous

Employees4,977
Market Cap$231.31 million
Next Earnings Date6/15/2020 (Estimated)
OptionableOptionable

Receive ARA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARA and its competitors with MarketBeat's FREE daily newsletter.


American Renal Associates (NYSE:ARA) Frequently Asked Questions

How has American Renal Associates' stock been impacted by COVID-19 (Coronavirus)?

American Renal Associates' stock was trading at $7.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ARA stock has decreased by 1.8% and is now trading at $7.01. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of American Renal Associates?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for American Renal Associates in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for American Renal Associates.

When is American Renal Associates' next earnings date?

American Renal Associates is scheduled to release its next quarterly earnings announcement on Monday, June 15th 2020. View our earnings forecast for American Renal Associates.

How were American Renal Associates' earnings last quarter?

American Renal Associates Holdings Inc (NYSE:ARA) issued its earnings results on Monday, March, 16th. The company reported $0.19 EPS for the quarter, beating the Zacks' consensus estimate of ($0.13) by $0.32. The company had revenue of $206.08 million for the quarter, compared to analyst estimates of $217.42 million. American Renal Associates had a negative net margin of 2.54% and a positive return on equity of 19.63%. View American Renal Associates' earnings history.

What price target have analysts set for ARA?

3 analysts have issued 12-month target prices for American Renal Associates' shares. Their forecasts range from $7.00 to $12.00. On average, they expect American Renal Associates' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 42.7% from the stock's current price. View analysts' price targets for American Renal Associates.

Has American Renal Associates been receiving favorable news coverage?

News stories about ARA stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. American Renal Associates earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View the latest news aboutAmerican Renal Associates.

Are investors shorting American Renal Associates?

American Renal Associates saw a drop in short interest in March. As of March 13th, there was short interest totaling 1,468,900 shares, a drop of 5.8% from the February 27th total of 1,560,000 shares. Based on an average daily trading volume, of 79,400 shares, the days-to-cover ratio is currently 18.5 days. Currently, 10.8% of the company's shares are short sold. View American Renal Associates' Current Options Chain.

Who are some of American Renal Associates' key competitors?

What other stocks do shareholders of American Renal Associates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other American Renal Associates investors own include Akorn (AKRX), Collegium Pharmaceutical (COLL), Exelixis (EXEL), Amicus Therapeutics (FOLD), KemPharm (KMPH), Madrigal Pharmaceuticals (MDGL), Mylan (MYL), Pattern Energy Group (PEGI), Catalyst Pharmaceuticals (CPRX) and Fate Therapeutics (FATE).

Who are American Renal Associates' key executives?

American Renal Associates' management team includes the following people:
  • Mr. Joseph A. Carlucci, Co-Founder, CEO & Chairman (Age 65)
  • Mr. Syed T. Kamal, Founder, Pres & Director (Age 66)
  • Mr. Mark C. Herbers, Interim CFO & Interim Chief Accounting Officer (Age 64)
  • Dr. Don E. Williamson, Exec. VP & COO (Age 56)
  • Mr. Richard Pacheco CFE, AVA, MBA, VP of Admin.

When did American Renal Associates IPO?

(ARA) raised $161 million in an initial public offering (IPO) on Thursday, April 21st 2016. The company issued 7,500,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

What is American Renal Associates' stock symbol?

American Renal Associates trades on the New York Stock Exchange (NYSE) under the ticker symbol "ARA."

Who are American Renal Associates' major shareholders?

American Renal Associates' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (3.18%), State Street Corp (1.07%), Geode Capital Management LLC (0.70%), California Public Employees Retirement System (0.23%), Bank of New York Mellon Corp (0.22%) and Strs Ohio (0.18%). View institutional ownership trends for American Renal Associates.

Which institutional investors are selling American Renal Associates stock?

ARA stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, California Public Employees Retirement System, Spark Investment Management LLC, Strs Ohio, Bank of America Corp DE, Geode Capital Management LLC, Goldman Sachs Group Inc., and Bank of New York Mellon Corp. View insider buying and selling activity for American Renal Associates.

Which institutional investors are buying American Renal Associates stock?

ARA stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, DekaBank Deutsche Girozentrale, State Street Corp, Financial Advisory Corp UT ADV, AQR Capital Management LLC, Tsfg LLC, Dynamic Technology Lab Private Ltd, and Jefferies Group LLC. View insider buying and selling activity for American Renal Associates.

How do I buy shares of American Renal Associates?

Shares of ARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is American Renal Associates' stock price today?

One share of ARA stock can currently be purchased for approximately $7.01.

How big of a company is American Renal Associates?

American Renal Associates has a market capitalization of $231.31 million and generates $822.52 million in revenue each year. The company earns $-13,790,000.00 in net income (profit) each year or $0.26 on an earnings per share basis. American Renal Associates employs 4,977 workers across the globe. View additional information about American Renal Associates.

What is American Renal Associates' official website?

The official website for American Renal Associates is http://www.americanrenal.com/.

How can I contact American Renal Associates?

American Renal Associates' mailing address is 500 CUMMINGS CENTER SUITE 6550, BEVERLY MA, 01915. The company can be reached via phone at 978-922-3080 or via email at [email protected]


MarketBeat Community Rating for American Renal Associates (NYSE ARA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  203 (Vote Outperform)
Underperform Votes:  236 (Vote Underperform)
Total Votes:  439
MarketBeat's community ratings are surveys of what our community members think about American Renal Associates and other stocks. Vote "Outperform" if you believe ARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: What is a Buy-Side Analyst?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel